All In Biotech

Drug Trial Radar · NCT01397461

Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo

A Phase III 3 Arms, Multicenter, Randomised, Investigator-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo

Last checked: Nov 19, 2026Latest source record: Jul 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 465 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

465

Actual

Start

Mar 2012

Primary completion

Dec 2012

Study completion Dec 2012

Sponsor

Lead sponsor
Ferrer Internacional S.A.Industry
Sponsor type
Industry
First posted
Jul 19, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is multicenter, randomised, placebo controlled, parallel, blinded (double-blind for ozenoxacin versus placebo comparison and investigator blinded for retapamulin versus placebo comparison), superiority clinical study comparing ozenoxacin cream versus placebo and retapamulin ointment vs placebo, in patients with a clinical diagnosis of non-bullous or bullous impetigo.

Conditions

  • Impetigo

Interventions

  • ozenoxacin placeboDrug

    cream

  • retapamulin 1% ointmentDrug

    ointment

  • ozenoxacin 1% creamDrug

    1% cream

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical SuccessTime frame: 2 weeks

Locations

19 sites in 2 countries. Site status is shown where the registry gives one.

  • Georg Popp

    Augsburg, Germany

  • Klaus Chelius

    Cologne, Germany

  • Roland Aschoff

    Dresden, Germany

  • Diamant Thaci

    Frankfurt am Main, Germany

  • Stephan Schilling

    Mahlow, Germany

  • Ismail Mitha

    Benoni, South Africa

  • Johan Lombaard

    Bloemfontein, South Africa

  • Jan Fourie

    Dundee, South Africa

  • Dawie Kruger

    George, South Africa

  • Philip Nel

    Hatfield, South Africa

  • Essack Mitha

    Johannesburg, South Africa

  • J Trokis

    Kraaifontein, South Africa

  • Mohammed Tayob

    Middelburg, South Africa

  • Mashra Gani

    Port Elizabeth, South Africa

  • Zelda Punt

    Port Elizabeth, South Africa

  • Molefe Phayane

    Pretoria, South Africa

  • Gail Todd

    Rondebosch, South Africa

  • Yacoob Vahed

    Welkom, South Africa

  • Christo van Dyk

    Worcester, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.